Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...